Praesidian Capital, a leading private investment firm, announced today that it acquired an integrated clinical and laboratory services company in the high-growth field of genetic medicine. The company is a leader in the prenatal and preconception field, and it also provides hereditary cancer risk assessments. This is Praesidian’s first acquisition as an independent sponsor and will serve as a strong platform as Praesidian looks to expand the business across the country.
“The company’s unique and scalable business model is ideally suited for the high-growth genetic testing industry,” stated Jason Drattell, Praesidian Founder. “This acquisition provides an exciting foundation for Praesidian’s independent sponsor platform.”
Glenn Harrison, Praesidian Capital Partner said: “Genetic testing is now an integral part of patient care. We have some of the best clinicians in the industry and are eager to expand the company’s service offerings and footprint while continuing to provide industry leading care.”
“We are very excited about closing our first deal as an independent sponsor,” noted Tom Duffy, Managing Director. “As we build our equity portfolio, we will be evaluating add-on acquisitions as well as subsequent platform deals.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: September 23, 2019
Source: Business Wire
